Abstract
Non-replicating vaccines, such as those based on recombinant proteins, require adjuvants and delivery systems, which have thus far depended on mimicking pathogen danger signals and strong pro-inflammatory responses. In search of a safer and more efficacious alternative, we tested whether vaccinations with influenza recombinant hemagglutinin (HA) mixed with a novel vegetable oil in water emulsion adjuvant (Natural Immune-enhancing Delivery System, NIDS), based on the immune-enhancing synergy of vitamins A and E and a catechin, could protect against intra-nasal challenge with live influenza virus. Vaccinations of inbred Brag Albino strain c (BALB/c) mice, with HA mixed with NIDS compared to other adjuvants, i.e., a squalene oil in water emulsion (Sq. oil), and the Toll Like Receptor 3 (TLR3) agonist Poly (I:C), induced significantly lower select innate pro-inflammatory responses in serum, but induced significantly higher adaptive antibody and splenic T Helper 1 (TH1) or TH2, but not TH17, responses. Vaccinations with NIDS protected against infection, as measured by clinical scores, lung viral loads, and serum hemagglutination inhibition titers. The NIDS exhibited a strong dose sparing effect and the adjuvant action of NIDS was in...Continue Reading
References
Jan 6, 1979·Lancet·T W HoskinsA Allchin
Jan 1, 1989·Advances in Experimental Medicine and Biology·Y Ghendon
May 15, 1996·Virology·B L Jacobs, J O Langland
May 5, 2001·Immunity·A Le BonD F Tough
Apr 6, 2004·Vaccine·Elawati SoenawanMichael Vajdy
Oct 14, 2004·Immunology and Cell Biology·Erik B Lindblad
Nov 17, 2004·The Pediatric Infectious Disease Journal·Paul M MendelmanBruce D Forrest
Nov 20, 2004·Immunology and Cell Biology·Michael VajdyManmohan Singh
Jan 18, 2006·Immunity·Kanta SubbaraoAnthony S Fauci
Feb 24, 2006·Emerging Infectious Diseases·Catherine J Luke, Kanta Subbarao
Sep 14, 2006·PLoS Medicine·Amorsolo L SuguitanKanta Subbarao
Sep 19, 2006·Lancet·Jiangtao LinWeidong Yin
Nov 1, 2006·Current Medicinal Chemistry·M Vajdy
May 2, 2007·The Journal of Experimental Medicine·Marie-Laure MichelMaria C Leite-de-Moraes
Aug 21, 2007·Lancet·Isabel Leroux-RoelsGeert Leroux-Roels
Dec 21, 2007·Journal of Virology·Caroline RuatAlbert D M E Osterhaus
Jan 3, 2008·PloS One·Benoît BarasAlbert D M E Osterhaus
Jan 26, 2008·Cytokine·Shabaana A Khader, Andrea M Cooper
Apr 29, 2008·Vaccine·Indresh SrivastavaMichael Vajdy
Jul 21, 2009·Human Vaccines·Gregory F Sonnenberg, David B Weiner
Dec 18, 2009·Journal of Virology·Sandesh SubramanyaPremlata Shankar
Jan 29, 2011·Vaccine·Mingke Yu, Michael Vajdy
Mar 23, 2011·Immunology Letters·Mingke YuMichael Vajdy
Mar 31, 2011·International Journal of Medical Sciences·Tamar A Smith-NorowitzMartin H Bluth
Oct 1, 2011·Expert Opinion on Biological Therapy·Michael Vajdy
Feb 10, 2012·PloS One·Cees C van den WijngaardMirjam Kretzschmar
Jun 8, 2012·Frontiers in Immunology·Ashish K MarwahaMegan K Levings
Jun 28, 2012·Microbiology and Immunology·Yuji MatsumotoTetsushi Yoshikawa
Feb 2, 2013·BMC Infectious Diseases·John J McKennaUNKNOWN 2009 Pandemic Influenza A (H1N1) Virus Hospitalizations Investigation Team
Jan 1, 2012·ISRN Inflammation·M S AhmedQing H Meng
Oct 9, 2013·The Journal of Experimental Medicine·Deanna A MeleJose M Lora
Mar 29, 2014·The Journal of Clinical Investigation·Tomohiro KogaGeorge C Tsokos
Jul 18, 2015·Expert Opinion on Biological Therapy·Sapna Patel, Michael Vajdy
May 3, 2016·Immunology·Sapna PatelMichael Vajdy
Oct 25, 2016·Vaccine·Marrit N HabetsDimitri A Diavatopoulos